182 related articles for article (PubMed ID: 34649782)
1. Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature.
Paschall A; Khan AA; Enam SF; Boggs T; Hijazi G; Bowling M; Austin S; Case LE; Kishnani P
Mol Genet Metab; 2021 Nov; 134(3):223-234. PubMed ID: 34649782
[TBL] [Abstract][Full Text] [Related]
2. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
[TBL] [Abstract][Full Text] [Related]
3. A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.
Hijazi G; Paschall A; Young SP; Smith B; Case LE; Boggs T; Amarasekara S; Austin SL; Pendyal S; El-Gharbawy A; Deak KL; Muir AJ; Kishnani PS
Mol Genet Metab Rep; 2021 Dec; 29():100821. PubMed ID: 34820282
[TBL] [Abstract][Full Text] [Related]
4. Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa.
Horvath JJ; Austin SL; Jones HN; Drake EJ; Case LE; Soher BJ; Bashir MR; Kishnani PS
Mol Genet Metab; 2012 Nov; 107(3):496-500. PubMed ID: 23062577
[TBL] [Abstract][Full Text] [Related]
5. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
Fernandes SA; Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
JIMD Rep; 2021 Jan; 57(1):94-101. PubMed ID: 33473345
[TBL] [Abstract][Full Text] [Related]
6. Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.
Verbeek RJ; Sentner CP; Smit GP; Maurits NM; Derks TG; van der Hoeven JH; Sival DA
Ultrasound Med Biol; 2016 Jan; 42(1):133-42. PubMed ID: 26437929
[TBL] [Abstract][Full Text] [Related]
7. Natural Progression of Canine Glycogen Storage Disease Type IIIa.
Brooks ED; Yi H; Austin SL; Thurberg BL; Young SP; Fyfe JC; Kishnani PS; Sun B
Comp Med; 2016 Feb; 66(1):41-51. PubMed ID: 26884409
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle].
Wang W; We M; Song HM; Qiu ZQ; Zhang WM; Wu XY; Lu CX; Qi JM; Jing H; Li F
Zhonghua Er Ke Za Zhi; 2009 Aug; 47(8):608-12. PubMed ID: 19951495
[TBL] [Abstract][Full Text] [Related]
9. Exercise intolerance in Glycogen Storage Disease Type III: weakness or energy deficiency?
Preisler N; Pradel A; Husu E; Madsen KL; Becquemin MH; Mollet A; Labrune P; Petit F; Hogrel JY; Jardel C; Maillot F; Vissing J; Laforêt P
Mol Genet Metab; 2013 May; 109(1):14-20. PubMed ID: 23507172
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa.
Du C; Wei H; Zhang M; Hu M; Li Z; Zhang C; Luo X; Liang Y
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):923-930. PubMed ID: 32623374
[TBL] [Abstract][Full Text] [Related]
11. An adult case of glycogen storage disease type IIIa.
Kim KO; Lee HJ; Choi JW; Eun JR; Choi JH
Korean J Hepatol; 2008 Jun; 14(2):219-25. PubMed ID: 18617770
[TBL] [Abstract][Full Text] [Related]
12. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease.
Horvath JJ; Austin SL; Case LE; Greene KB; Jones HN; Soher BJ; Kishnani PS; Bashir MR
Muscle Nerve; 2015 May; 51(5):722-30. PubMed ID: 25155446
[TBL] [Abstract][Full Text] [Related]
13. Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.
Halaby CA; Young SP; Austin S; Stefanescu E; Bali D; Clinton LK; Smith B; Pendyal S; Upadia J; Schooler GR; Mavis AM; Kishnani PS
Genet Med; 2019 Dec; 21(12):2686-2694. PubMed ID: 31263214
[TBL] [Abstract][Full Text] [Related]
14. Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.
Olgac A; İnci A; Okur İ; Biberoğlu G; Oğuz D; Ezgü FS; Kasapkara ÇS; Aktaş E; Tümer L
Ann Nutr Metab; 2020; 76(4):233-241. PubMed ID: 32712609
[TBL] [Abstract][Full Text] [Related]
15. The electrodiagnostic characteristics of Glycogen Storage Disease Type III.
Hobson-Webb LD; Austin SL; Bali DS; Kishnani PS
Genet Med; 2010 Jul; 12(7):440-5. PubMed ID: 20071996
[TBL] [Abstract][Full Text] [Related]
16. Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study.
Hennis PJ; Murphy E; Meijer RI; Lachmann RH; Ramachandran R; Bordoli C; Rayat G; Tomlinson DJ
Orphanet J Rare Dis; 2022 Jan; 17(1):28. PubMed ID: 35101075
[TBL] [Abstract][Full Text] [Related]
17. Mouse model of glycogen storage disease type III.
Liu KM; Wu JY; Chen YT
Mol Genet Metab; 2014 Apr; 111(4):467-76. PubMed ID: 24613482
[TBL] [Abstract][Full Text] [Related]
18. Skeletal and cardiac muscle involvement in children with glycogen storage disease type III.
Mogahed EA; Girgis MY; Sobhy R; Elhabashy H; Abdelaziz OM; El-Karaksy H
Eur J Pediatr; 2015 Nov; 174(11):1545-8. PubMed ID: 25948107
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy in glycogen storage disease type III: Fact or myth?
Herlin B; Laforět P; Labrune P; Fournier E; Stojkovic T
Muscle Nerve; 2016 Feb; 53(2):310-2. PubMed ID: 26575860
[TBL] [Abstract][Full Text] [Related]
20. Correction of glycogen storage disease type III with rapamycin in a canine model.
Yi H; Brooks ED; Thurberg BL; Fyfe JC; Kishnani PS; Sun B
J Mol Med (Berl); 2014 Jun; 92(6):641-50. PubMed ID: 24509886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
